TSS
CLDI icon

Two Sigma Securities’s Calidi Biotherapeutics CLDI Stock Holding History

Two Sigma Securities’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,688
Closed -$11.5K – 1574
2025
Q1 		$11.5K Buy
+1,688
New +$19.2K ﹤0.01% 1209
2024
Q3 		– Sell
-93
Closed -$2.23K – 2958
2024
Q2 		$2.23K Buy
+93
New +$2.97K ﹤0.01% 2886

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Securities's CLDI Position: Q2 2025 in Review

Two Sigma Securities sold out of Calidi Biotherapeutics (CLDI) in Q2 2025, closing a stake of 1,688 shares — an estimated $11.5K sold.

Two Sigma Securities first reported a position in CLDI in Q2 2024 and held it in 2 quarters. The position peaked at $11.5K in Q1 2025. 35 funds tracked by Wall St. Rank hold CLDI as of Q2 2025.

  • Two Sigma Securities reported no remaining Calidi Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Securities sold 1,688 Calidi Biotherapeutics shares in Q2 2025, an estimated $11.5K.
  • Two Sigma Securities first reported a position in Calidi Biotherapeutics in Q2 2024 and held it in 2 quarters.
  • Two Sigma Securities's Calidi Biotherapeutics position peaked at $11.5K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.